CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HER2-low 与三阴性乳腺癌中的 TIL（肿瘤浸润淋巴细胞）：它们有关联吗？
英文原题：HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
查看英文原题
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
大多数三阴性乳腺癌（TNBC）患者不适合靶向治疗，化疗仍是主要治疗选择。近年来，由于TNBC具有免疫原性，免疫治疗在TNBC中显示出有希望的结果。
此外，一种新型抗体药物偶联物，即trastuzumab-deruxtecan，已在低HER2表达（HER2-low）的TNBC患者中显示出有效性。这些新型治疗选择提出了关于间质TIL（肿瘤浸润淋巴细胞）（sTILs）密度与HER2表达水平之间潜在关联的问题。
我们旨在评估TNBC患者中HER2表达水平（HER2-low与HER2-0）与sTILs密度之间的关联，以及它们如何影响对新辅助化疗（NAC）的反应。这是一项回顾性多中心研究，纳入了2018年至2022年间诊断的所有TNBC患者。中心病理复核包括sTILs百分比和HER2表达水平。肿瘤被重新分类为HER2-0（HER2 IHC 0）或HER2-low（IHC 1+或2+且反射试验阴性）。比较了HER2-0与HER2-low病例之间的各种临床病理特征，包括sTILs密度和对NAC的反应。
本研究共纳入753例TNBC患者，其中292例接受了NAC。原始病理报告与中心复核之间的观察者间一致性为中等（77%的病例在重新分类为HER2-0或HER2-low后具有相同的IHC状态；k = 0.45）。HER2-low TNBC约占肿瘤的三分之一（36%）。HER2-0与HER2-low病例之间未发现sTILs密度或完全病理缓解率存在显著差异（分别为p = 0.476和p = 0.339）。sTILs密度（≥ 10% sTILs vs.< 10%）与达到 pCR 独立相关（p = 0.011）。
总之，HER2-low 状态与 sTILs 密度及 NAC 反应之间未发现显著关联。尽管如此，sTILs 可能是预测 TNBC 患者 NAC 反应的独立生物标志物。
展开英文摘要原文
Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity.
In addition, a novel antibody-drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low). These novel treatment options raise the question about the potential association between the density of stromal tumor-infiltrating lymphocytes (sTILs) and the level of HER2 expression.
We aimed to evaluate the association between the level of HER2 expression (HER2-low versus HER2-0) and density of sTILs in TNBC patients, and how they impact the response to neoadjuvant chemotherapy (NAC). This was a retrospective multicenter study including all TNBC patients diagnosed between 2018 and 2022. Central pathology review included sTILs percentages and level of HER2 expression. Tumors were reclassified as either HER2-0 (HER2 IHC 0) or HER2-low (IHC 1 + or 2 + with negative reflex test). Various clinicopathologic characteristics, including sTILs density, and response to NAC were compared between HER2-0 and HER2-low cases.
In total, 753 TNBC patients were included in this study, of which 292 patients received NAC. Interobserver agreement between the original pathology report and central review was moderate (77% had the same IHC status after reclassification in either HER2-0 or HER2-low; k = 0. 45).
HER2-low TNBC represented about one third (36%) of the tumors. No significant difference in sTILs density or complete pathologic response rate was found between HER2-0 and HER2-low cases (p = 0. 476 and p = 0. 339, respectively). The density of sTILs (≥ 10% sTILs vs. < 10%) was independently associated with achieving a pCR (p = 0. 011).
In conclusion, no significant association was found between HER2-low status and density of sTILs nor response to NAC. Nonetheless, sTILs could be an independent biomarker for predicting NAC response in TNBC patients.
论文信息
- 作者
- Baez-Navarro X、van den Ende NS、Nguyen AH、Sinke R、Westenend P、van Brakel JB、Stobbe C、Westerga J
- 单位
- Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands. x.baeznavarro@erasmusmc.nl.Netherlands
- 文献类型
- 多中心研究 · 非美国政府资助研究
- 期刊
- Breast cancer research : BCR2024 Mar 11
- 原文标识
- PubMed 38468323 · DOI 10.1186/s13058-024-01783-z
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →